中国医药指南
中國醫藥指南
중국의약지남
CHINA MEDICINE GUIDE
2015年
2期
48-49
,共2页
饶建%林秀欣%李春鸣%余更生
饒建%林秀訢%李春鳴%餘更生
요건%림수흔%리춘명%여경생
双肺多发转移癌%全肺放疗
雙肺多髮轉移癌%全肺放療
쌍폐다발전이암%전폐방료
Multiple double-pulmonary metastases%Palliative irradiation
目的:探讨姑息放疗治疗双肺多发转移癌的价值。方法1999年3月至2007年5月我院肿瘤科收治38例双肺多发肺转移癌患者,均给予姑息放疗。现对这些患者的临床资料进行总结分析。结果本组放疗结束时转移瘤CR率为15.8%(6/38),PR率为50.0%(19/38),有效率(PR+CR)达65.8%。原发肿瘤为鼻咽癌、乳腺癌、肝癌、结直肠癌的中位生存期分别为13.5、22.0、6、8.5个月。1~2级放射性肺炎发生率为26.3%(10/38);3级为15.8%(6/38);4~5级为0。结论恶性肿瘤肺多发转移可以采用全肺放疗+局部小野补量治疗,尤其适用于原发肿瘤对放疗中高度敏感、化疗有效的患者,可获得较好疗效。不良反应可耐受。
目的:探討姑息放療治療雙肺多髮轉移癌的價值。方法1999年3月至2007年5月我院腫瘤科收治38例雙肺多髮肺轉移癌患者,均給予姑息放療。現對這些患者的臨床資料進行總結分析。結果本組放療結束時轉移瘤CR率為15.8%(6/38),PR率為50.0%(19/38),有效率(PR+CR)達65.8%。原髮腫瘤為鼻嚥癌、乳腺癌、肝癌、結直腸癌的中位生存期分彆為13.5、22.0、6、8.5箇月。1~2級放射性肺炎髮生率為26.3%(10/38);3級為15.8%(6/38);4~5級為0。結論噁性腫瘤肺多髮轉移可以採用全肺放療+跼部小野補量治療,尤其適用于原髮腫瘤對放療中高度敏感、化療有效的患者,可穫得較好療效。不良反應可耐受。
목적:탐토고식방료치료쌍폐다발전이암적개치。방법1999년3월지2007년5월아원종류과수치38례쌍폐다발폐전이암환자,균급여고식방료。현대저사환자적림상자료진행총결분석。결과본조방료결속시전이류CR솔위15.8%(6/38),PR솔위50.0%(19/38),유효솔(PR+CR)체65.8%。원발종류위비인암、유선암、간암、결직장암적중위생존기분별위13.5、22.0、6、8.5개월。1~2급방사성폐염발생솔위26.3%(10/38);3급위15.8%(6/38);4~5급위0。결론악성종류폐다발전이가이채용전폐방료+국부소야보량치료,우기괄용우원발종류대방료중고도민감、화료유효적환자,가획득교호료효。불량반응가내수。
Objective To investigate the whole-lung irradiation value on the pulmonary metastases. Methods From March 1999 to May 2003, there were 24 patients with multiple double-pulmonary metastases accepted whole-lung irradiation in the department of oncology, Jiangmen center hospital. Data of the 24 patients were retrospectively analyzed. Results After radiotherapy, the complete response rate of lung transferring tumor was 15.8%(6/38), partial response rate was 50.0%(19/38)and the overall response rate(PR+CR)was 65.8%. As the primary tumor was nasopharyngeal carcinoma, breast cancer, liver cancer, colonic and rectal cancer, the median survival time was 13.5, 22.0, 10.5, 8.5 months, respectively. Grade 1-2 radiation pneumonitis were 26.3%(10/38), grade 3 were 15.8%(6/38), grade 4-5 were 0. Conclusion Whole-lung irradiation plus local boost is able to treat pulmonary metastases of malignant tumor. It’s applicable especially to the patient whose primary tumor is sensitive to radiotherapy and no response to chemotherapy. The curative effect is satisfaction and the side effects are acceptable.